Predict your next investment

HEALTHCARE | Biotechnology
avontec.com

See what CB Insights has to offer

Founded Year

2001

Stage

Series B | Dead

Total Raised

$23.21M

Last Raised

$17.83M

About Avontec

Developer of nucleic acid-based anti-inflammatory drugs for the treatment of asthma, psoriasis, and rheumatoid arthritis. The company develops drugs based on oligonucleotides which act as decoys for disease-related transcription factors. It also develops programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease, and autoimmune disease. [Keyword: deoxyribonucleic acid (DNA)]

Avontec Headquarter Location

Fraunhoferstrasse 15

Martinsried, 82152,

Germany

49 89 856 51 600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Avontec Patents

Avontec has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/12/2003

8/17/2010

Molecular biology, Genetics, DNA, Nucleic acids, Biotechnology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/12/2003

00/00/0000

00/00/0000

Grant Date

8/17/2010

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Genetics, DNA, Nucleic acids, Biotechnology

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.